The oxazolidinones: past, present, and future.

doi:10.1111/j.1749-6632.2011.06330.x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

The oxazolidinones: past, present, and future.

Annals of the New York Academy of Sciences - 1 Dec 2011

Shaw Karen Joy, Barbachyn Michael R

Abstract excerpt

The success of linezolid stimulated significant efforts to discover new agents in the oxazolidinone class. Over a dozen oxazolidinones have reached the clinic, but many were discontinued due to lack of differentiated potency, inadequate pharmacokinetics, and safety risks that included myelosuppression. Four oxazolidinones are currently undergoing clinical evaluation. The Trius Therapeutics compound tedizolid...

Topics

Anti-Bacterial Agents
Bacterial Infections
Clinical Trials as Topic
Drug Resistance, Bacterial
Genes, Bacterial
History, 20th Century
History, 21st Century
Humans
Mutation
Oxazolidinones

Source

Open in PubMed

Identifiers

PMID: 22191526
DOI: 10.1111/j.1749-6632.2011.06330.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics